Galapagos is specialized in the discovery and early development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech: four programs in development and over 30 pre-clinical candidate and discovery programs.
Galapagos has a strong investor base, with a long term commitment to the biotech industry. Whether you are a current investor in Galapagos or are evaluating Galapagos as a potential investment opportunity, we welcome you to contact us should you have any additional questions after reviewing our website.
For all your investor relations questions and to request receipt of press releases, annual reports, and other materials:
Head of Corporate Communications & Investor Relations
Mobile: +31 622916240